Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 4, 2003. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs) resulting from movements in employee benefit plans and share option exercises.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity ownership changes within employee benefit trusts and retirement plans.
Material Changes
- GlaxoSmithKline US Retirement Savings Plan: On January 30, 2003, holdings decreased from 18,287,511 to 18,261,048 ADRs at an average price of $36.30. On January 31, 2003, holdings increased from 18,261,048 to 18,296,820 ADRs at an average price of $38.76.
- SmithKline Beecham Employee Benefit Trust: On January 31, 2003, 20,106 Ordinary shares were transferred from the Trust to participants of the 1991 Share Option Plan.
- Director Specific Interest: Dr. J.P. Garnier increased his personal interest by 74 Ordinary Share ADRs on January 31, 2003, at a price of $38.76 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The disclosures relate to standard administrative updates regarding director shareholdings linked to discretionary employee funds.
Key Facts for Investor Verification
- Directors Dr. J.P. Garnier and Mr. J.D. Coombe hold interests in the GlaxoSmithKline US Retirement Savings Plan and the SmithKline Beecham Employee Benefit Trust in the same capacity as other employees.
- Share price fluctuations between $36.30 and $38.76 per ADR were recorded during the reporting period.
- Net movement in the US Retirement Savings Plan resulted in an increase of approximately 35,000 ADRs over the two-day period (Jan 30-31).